Lantheus (NASDAQ:LNTH – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.30 per share and revenue of $363.19 million for the quarter. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.
Lantheus (NASDAQ:LNTH – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.53 earnings per share. On average, analysts expect Lantheus to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Lantheus Stock Up 1.6%
LNTH stock opened at $101.19 on Tuesday. The stock has a market capitalization of $6.59 billion, a P/E ratio of 24.38 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. Lantheus has a one year low of $47.25 and a one year high of $111.86. The company has a 50 day moving average price of $103.96 and a two-hundred day moving average price of $87.12.
Analysts Set New Price Targets
Check Out Our Latest Analysis on Lantheus
Key Stories Impacting Lantheus
Here are the key news stories impacting Lantheus this week:
- Positive Sentiment: Curium will pay $102.50 per Lantheus share in cash at closing, plus non-transferable contingent value rights (CVRs) worth up to an additional $12 per share if specified product-sales milestones are achieved through 2030. The maximum consideration is therefore $114.50 per share. Curium deepens radiopharma heft with up to $8 billion deal for Lantheus
- Positive Sentiment: The cash offer provides near-term value and represents a stated 38% premium to Lantheus’ unaffected 60-day volume-weighted average price. An analyst described the buyout as an “excellent outcome” for shareholders. Analyst calls Curium’s $8 billion Lantheus buyout an excellent outcome for shareholders
- Positive Sentiment: Lantheus’ board unanimously approved the transaction after reviewing strategic alternatives, including remaining independent. The combination would unite Lantheus’ U.S. radiodiagnostics business with Curium’s global manufacturing and radiotherapeutics platform across oncology, neurology and cardiology markets in more than 70 countries. Curium Announces Definitive Agreement to Merge with Lantheus
- Neutral Sentiment: The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals. Until closing, Lantheus will remain publicly traded; afterward, it will become a private company. The stock’s trading level near the $102.50 cash offer suggests investors are primarily valuing the certain cash payment, while assigning less value to the conditional CVRs.
- Negative Sentiment: Several shareholder law firms, including Ademi, Halper Sadeh and Monteverde & Associates, announced investigations into whether Lantheus’ directors obtained a fair price or breached fiduciary duties. Such reviews are common in merger announcements but could create legal costs, delays or pressure for improved terms. Halper Sadeh Lantheus investigation
- Negative Sentiment: Lantheus suspended its previously issued fiscal 2026 guidance and will not host a conference call with its second-quarter results, scheduled for August 6. The move limits near-term visibility into standalone operating performance, while the CVR payments remain uncertain because they depend on future sales milestones.
Hedge Funds Weigh In On Lantheus
Hedge funds have recently made changes to their positions in the stock. Alberta Investment Management Corp purchased a new stake in shares of Lantheus during the 4th quarter valued at $1,617,000. Vident Advisory LLC raised its position in shares of Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after buying an additional 230 shares during the period. Mackenzie Financial Corp raised its position in shares of Lantheus by 31.1% in the 4th quarter. Mackenzie Financial Corp now owns 657,674 shares of the medical equipment provider’s stock worth $44,082,000 after buying an additional 156,081 shares during the period. XTX Topco Ltd boosted its holdings in Lantheus by 64.8% in the fourth quarter. XTX Topco Ltd now owns 18,440 shares of the medical equipment provider’s stock valued at $1,227,000 after acquiring an additional 7,252 shares during the last quarter. Finally, Vestal Point Capital LP boosted its holdings in Lantheus by 111.8% in the fourth quarter. Vestal Point Capital LP now owns 360,000 shares of the medical equipment provider’s stock valued at $23,958,000 after acquiring an additional 190,000 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.
The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.
Read More
- Five stocks we like better than Lantheus
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
